Iptacopan helps control the alternative complement pathway by binding to Factor B.
This regulation includes managing the cleavage of C3, influencing downstream effects, and controlling the amplification of the terminal pathway.
In conditions like PNH, Iptacopan plays a role in preventing intravascular hemolysis (IVH) caused by the membrane attack complex (MAC) and also helps control extravascular hemolysis (EVH) by affecting C3b opsonization.
It acts early in the complement cascade to manage both C3b-mediated EVH and terminal complement-mediated IVH.